Superluminal raises $60M to move its GPCR obesity drug into Phase 1

Why it matters

Superluminal has raised $213M across disclosed rounds and entered a Lilly collaboration before reaching the clinic. Phase 1 will test whether its GPCR platform can produce a differentiated medicine.

Superluminal Medicines, co-founded by CEO Cony D'Cruz and senior vice president and head of discovery Ajay Yekkirala, closed a $60 million Series B on September 3, 2026 to move its first drug into human testing by the end of 2026.

The financing puts D'Cruz and Yekkirala at the point where years of computational modeling, structural biology and medicinal chemistry have to produce evidence in patients. Superluminal says the money will fund a Phase 1 trial of an oral MC4R agonist for rare genetic forms of obesity and hypothalamic obesity, alongside work on additional drug programs and its GPCR discovery platform.

D'Cruz spent much of his career turning computational drug discovery into partnerships, with senior roles at Evotec, Proteros and Schrodinger before launching Superluminal in 2023. Yekkirala brings the receptor biology. He earned a Ph.D. in pharmacology at the University of Minnesota under opioid pharmacologist Philip Portoghese, then completed postdoctoral training with pain researcher Clifford Woolf at Harvard Medical School. He founded non-addictive pain drug developer Blue Therapeutics and later worked at RA Capital Management.

Their shared bet is that better models of how receptors move can produce small molecules with more precise effects. Phase 1 will provide the first human evidence for that thesis.

The round pays for a clinical transition

BVF Partners led the Series B. New investors Deep Track Capital and Perceptive Advisors joined existing backers RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly, Cooley and Gaingels.

Superluminal described the round as oversubscribed without specifying the demand or target size. The disclosed financing takes Superluminal's total across three rounds to $213 million: a $33 million seed in August 2023, a $120 million Series A in September 2024 and the new Series B.

That is a substantial capital base for a drug developer whose pipeline remains preclinical. The investor list combines specialist biotech funds with a major pharmaceutical partner and NVIDIA's venture arm.

The lead program activates melanocortin-4 receptor, or MC4R, which regulates appetite, energy use and body weight. Superluminal is developing a biased agonist, meaning the molecule is designed to favor selected signaling pathways rather than trigger every effect associated with the receptor.

According to Superluminal's pipeline materials, the approach is intended to preserve the desired appetite and weight effects while reducing activity associated with unwanted side effects. Superluminal describes the candidate as selective and biased, but those claims remain preclinical and have not been tested in humans.

AI now has to earn its place in the molecule

Superluminal calls its discovery system Hyperloop. The platform combines protein-dynamics modeling, large-scale virtual screening, generative molecule design, predictive drug-metabolism and toxicity tools, and experimental structural biology.

The premise is that GPCRs should be modeled as moving proteins with multiple possible shapes instead of single static structures.

That distinction matters for biased signaling. A molecule's effect can change depending on which receptor shape it stabilizes and which downstream pathway that shape activates. D'Cruz and Yekkirala are using machine learning to search those conformations, while lab experiments supply the structural and biological checks.

The financing does not validate that system by itself. A syndicate can validate investor interest, and a pharmaceutical collaboration can validate commercial relevance. The lead drug's safety, tolerability and biological activity will depend on clinical data.

Under an August 2025 collaboration with Eli Lilly, Superluminal agreed to apply its platform to undisclosed GPCR targets in cardiometabolic disease and obesity. Lilly would receive exclusive development and commercialization rights to compounds arising from the collaboration after Superluminal delivered candidates meeting predefined criteria.

Superluminal says the arrangement could be worth up to $1.3 billion through upfront and near-term payments, an equity investment, development and commercial milestones, and tiered royalties. Much of the headline value is contingent on producing drugs that progress through development and reach the market.

Rhythm has already proved the target

Superluminal enters a field with clinical and commercial precedent. Rhythm Pharmaceuticals' injectable MC4R agonist Imcivree is approved for obesity associated with Bardet-Biedl syndrome and several other rare genetic conditions. The FDA also expanded its approval in March 2026 to cover acquired hypothalamic obesity in adults and children aged four and older.

That approval confirms MC4R as a viable drug target and gives Superluminal a clear comparator. It also raises the standard for differentiation. Human data will determine whether Superluminal's design translates into a meaningful clinical advantage.

Superluminal's candidate is designed as an oral treatment with greater receptor selectivity, D'Cruz told BioPharma Dive. Superluminal's July 2025 program update also presented the molecule as a possible way to reduce skin-darkening and cardiovascular effects associated with earlier MC4R programs. Human data will determine whether that design translates into a meaningful clinical advantage.

The immediate plan centers on rare genetic and hypothalamic obesity, where the biology is well defined and MC4R already has regulatory validation. Superluminal has separately described broader use alongside GLP-1 drugs, potentially as a combination or maintenance treatment for general obesity. That opportunity sits beyond the first clinical study.

For D'Cruz and Yekkirala, the year-end Phase 1 target marks a clean change in the job. Superluminal has raised the capital, built the models and found pharmaceutical partners. The next stage belongs to the molecule.